Myocardial Infarction After Carotid Stenting and Endarterectomy
- 7 June 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 123 (22), 2571-2578
- https://doi.org/10.1161/circulationaha.110.008250
Abstract
Background— The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) found a higher risk of stroke after carotid artery stenting and a higher risk of myocardial infarction (MI) after carotid endarterectomy. Methods and Results— Cardiac biomarkers and ECGs were performed before and 6 to 8 hours after either procedure and if there was clinical evidence of ischemia. In CREST, MI was defined as biomarker elevation plus either chest pain or ECG evidence of ischemia. An additional category of biomarker elevation with neither chest pain nor ECG abnormality was prespecified (biomarker+ only). Crude mortality and risk-adjusted mortality for MI and biomarker+ only were assessed during follow-up. Among 2502 patients, 14 MIs occurred in carotid artery stenting and 28 MIs in carotid endarterectomy (hazard ratio, 0.50; 95% confidence interval, 0.26 to 0.94; P=0.032) with a median biomarker ratio of 40 times the upper limit of normal. An additional 8 carotid artery stenting and 12 carotid endarterectomy patients had biomarker+ only (hazard ratio, 0.66; 95% confidence interval, 0.27 to 1.61; P=0.36), and their median biomarker ratio was 14 times the upper limit of normal. Compared with patients without biomarker elevation, mortality was higher over 4 years for those with MI (hazard ratio, 3.40; 95% confidence interval, 1.67 to 6.92) or biomarker+ only (hazard ratio, 3.57; 95% confidence interval, 1.46 to 8.68). After adjustment for baseline risk factors, both MI and biomarker+ only remained independently associated with increased mortality. Conclusions— In patients randomized to carotid endarterectomy versus carotid artery stenting, both MI and biomarker+ only were more common with carotid endarterectomy. Although the levels of biomarker elevation were modest, both events were independently associated with increased future mortality and remain an important consideration in choosing the mode of carotid revascularization or medical therapy. Clinical Trial Registration— URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00004732.This publication has 36 references indexed in Scilit:
- Protected Carotid-Artery Stenting versus Endarterectomy in High-Risk PatientsThe New England Journal of Medicine, 2004
- Troponin T‐values provide long‐term prognosis in elderly patients undergoing non‐cardiac surgeryActa Anaesthesiologica Scandinavica, 2004
- Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary InterventionCirculation, 2004
- Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgeryJournal of the American College of Cardiology, 2003
- Cardiac Troponin I Predicts Short-Term Mortality in Vascular Surgery PatientsCirculation, 2002
- Diagnosis of Myocardial Injury by Biochemical Markers: Problems and PromisesCardiology in Review, 2002
- Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct sizeHeart, 2002
- Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: A multinational registry of patients hospitalized with acute coronary syndromesAmerican Heart Journal, 2001
- CREST (Carotid Revascularization Endarterectomy versus Stent Trial): background, design, and current status.2000
- Prognostic Value of Cardiac Troponin T After Noncardiac Surgery: 6-Month Follow-Up DataJournal of the American College of Cardiology, 1997